Friday’s pre-market futures are in the green at this hour, though a little choppy. One new economic report and a handful of Q2 earnings releases ahead of the opening bell are perhaps having some impact, but over the past week of trading — which has been positive across the board — we’re seeing a bit of moderation at or near all-time highs.The Dow is +55 points at this hour, while the S&P 500 is +8 points and the Nasdaq +6. The small-cap Russell 2000 is +8 points currently. Over the past five days of trading ...

Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call and webcast on Monday, July 28 at 8: ...

Core Insights - Viking Therapeutics reported significant clinical and financial developments in Q2 2025, including the initiation of the Phase 3 VANQUISH program for VK2735, aimed at treating obesity and type 2 diabetes [2][4] - The company ended the quarter with a strong cash position of $808 million, supporting ongoing clinical trials and development programs [5][16] Clinical Pipeline Updates - The VANQUISH Phase 3 program for VK2735 includes two studies targeting approximately 4,500 adults with obesity and 1,100 adults with type 2 diabetes, assessing the efficacy and safety of VK2735 administered weekly for 78 weeks [4][5] - The Phase 2 VENTURE-Oral Dosing study of VK2735's oral formulation completed enrollment with approximately 280 patients, with top-line results expected in the second half of 2025 [6][8] - VK2735 demonstrated statistically significant weight loss of up to 14.7% in previous trials, with a favorable safety profile [3][4] Financial Performance - Research and development expenses for Q2 2025 were $60.2 million, up from $23.8 million in Q2 2024, primarily due to increased clinical study costs [10][11] - General and administrative expenses rose to $14.4 million in Q2 2025 from $10.3 million in Q2 2024, driven by higher stock-based compensation [11] - The net loss for Q2 2025 was $65.6 million, compared to a net loss of $22.3 million in Q2 2024, reflecting increased operational costs [12] Balance Sheet Overview - As of June 30, 2025, Viking held cash, cash equivalents, and short-term investments totaling $808 million, a decrease from $903 million at the end of 2024 [16] - The total liabilities stood at $32.4 million, with stockholders' equity at $795.5 million [25]

If you've ever played the New York Times Connections game, you know it can be challenging. That said it. What.How do I mix it up. The game's notoriety was recently part of a joke on Saturday Night Live. So this order will make the New York Times Connections game easier.And it's about time. Every time it's like, how the hell was I going to get that fourth one. Of course, this isn't a video about connections.This is about how President Trump has been using executive orders to reshape government and society in ...

Jinghan Hu, a student majoring in Food Nutrition and Health, shared her story of fighting against eating disorders. She said that our lives are like probiotics fermenting in a cellular room—growing in our own form, not to be disciplined by a single standard. There has never been a unified standard or definition for life. We don't need anyone's labels to prove ourselves.食品营养与健康专业的胡静函，讲述了自己对抗进食障碍的故事。她说，我们的生命，就像细胞房中正在发酵的益生菌——用自己的形态生长，不必被单一标准规训。生命从没有统一的标准与定义。我们也不需要谁的标签来证明自己。 Healthy Diet Promoter Leader of Coll ...

Protecting your freedom of speechGlobal Government Affairs (@GlobalAffairs):In a victory for transparency and free speech, the D.C. Circuit Court of Appeals has unanimously ruled in X’s favor to limit the U.S. government’s ability to issue gag orders. These gag orders prevent X from notifying the public when it receives government search warrants and ...

Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Eye Spear Market (By Product Type, Segment, Application, End-User, Sales Channel, Regional Analysis), Company Profiles, Eye Spear Product Details, Pictures, Recent Developments and Market Dynamics - Global Forecast (2025 - 2032)" report has been added to ResearchAndMarkets.com's offering. The global eye spear market is projected to reach US$ 265.6 Million by 2032, from US$ 162.7 Million in 2024. The application of eye spears extends across a range of surgical ...

From @WSJopinion: I was Jeffrey Epstein’s lawyer. I know the facts, some of which I can’t disclose because it is privileged or subject to court-imposed sealing orders. But what I can disclose makes several important things clear, writes @AlanDersh. https://t.co/t3jbVhEW3N ...

Company Overview - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company leverages its expertise in metabolism to create innovative therapeutics aimed at improving patients' lives [3] Clinical Programs - Viking's clinical programs include VK2735, a dual agonist of GLP-1 and GIP receptors, currently evaluated in a Phase 3 obesity program with two trials (VANQUISH-1 and VANQUISH-2) [3] - VK2735 has shown an encouraging safety and tolerability profile along with positive clinical benefits in Phase 1 and Phase 2 trials [3] - An oral formulation of VK2735 is also being evaluated in a Phase 2 trial for obesity [3] - VK2809, a small molecule selective thyroid hormone receptor beta agonist, has achieved primary and secondary endpoints in a Phase 2b study for NASH and fibrosis [3] - In a Phase 2a trial for NAFLD and elevated LDL-C, VK2809 demonstrated statistically significant reductions in LDL-C and liver fat compared to placebo [3] - The company is developing dual amylin and calcitonin receptor agonists (DACRAs) for obesity and metabolic disorders [3] - VK0214, another small molecule selective thyroid hormone receptor beta agonist, is in development for X-ALD and has shown safety and significant reductions in VLCFAs in a Phase 1b trial [3] Upcoming Events - Viking Therapeutics will release its financial results for Q2 2025 after market close on July 23, 2025 [1] - A conference call to discuss these results and corporate updates is scheduled for July 23, 2025, at 4:30 p.m. Eastern Time [2]

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion. Th ...